Shivam Singh

Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF…

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subcutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma

October 28, 2026 20:25 ET  | Source: Junshi Biosciences SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for the company’s product, toripalimab

PharmaShots Newsroom press release graphic

Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer

October 28, 2026 07:00 ET  | Source: Adagene Inc. Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver metastases SAN DIEGO and SUZHOU, China, Oct. 28, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq:

Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF…

Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026

October 27, 2026 23:48 ET  | Source: Junshi Biosciences SHANGHAI, Oct. 27, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the final analysis results from the Phase 3 NEOTORCH study (NCT04158440)

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative…

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

October 27, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that it has completed the acquisition of assets from BioXcel Therapeutics, Inc., including worldwide rights to BXCL501. BXCL501

PharmaShots Newsroom press release graphic

Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

October 27, 2026 07:00 ET  | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in a fireside chat and one-on-one meetings at the

PharmaShots Newsroom press release graphic

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

October 24, 2026 02:30 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the randomized dose-optimization portion of its ongoing Phase

Scroll to Top